Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Table 2 Number of bound CD20 antibodies per lymphoma cell before and after valproate treatment

*Patient*	*Valproate dosage* (mg/kg/day)	*Day 0*		*Day 3*
*Patient*	*Valproate dosage* (mg/kg/day)	*MFI*	*Bound CD20 mAbs per cell*	*MFI*	*Bound CD20 mAbs per cell*	*Plasma valproate (μM)*
003	30	2163	6866	7602	18035	*407
008	80	30893	70229	34322	78890	656
010	80	35540	69096	41605	79260	847

An FNB of an affected lymph node was performed before treatment start as well as morning day 3, cycle 1 in patients 003, 008 and 010 of the VALFRID study. Lymphoma cells (i.e., monoclonal B-cells) were analysed by FACS as described in materials and methods, and the number of bound CD20 antibodies to the cell surface was calculated by normalisation by the QuantiBRITE assay using geometric mean fluorescence intensity (MFI). Corresponding doses and serum levels of valproate are indicated (*: Day 2).

ISSN: 2162-3619